NHRC Initiates Action Over Substandard Epilepsy Drug In Delhi Hospitals

New Delhi: The National Human Rights Commission (NHRC) of India has taken suo motu cognizance of a concerning media report indicating that the medicine ‘Sodium Valproate,’ recommended for the treatment of epilepsy in Delhi government-run hospitals and Mohalla Clinics, does not meet the required standards. This revelation stems from a report issued by the Regional Drug Testing Laboratory (RDTL) in Chandigarh. Additionally, another medication prescribed by doctors for epilepsy treatment was also found to be substandard.

As per the Directorate of Vigilance’s released report, a total of 43 medicine samples underwent examination in government laboratories. Out of these, four samples failed the test, while the results for 11 samples are still pending.

The NHRC deems the information from the news report, if accurate, as a serious violation of human rights, warranting concern. Consequently, the Commission has issued notices to the Delhi Chief Secretary, the Drugs Controller General of India, and the Police Commissioner, requesting a comprehensive report within four weeks.

The media report, dated December 28, 2023, highlights that five medicines have been banned to date, including those prescribed for hypertension, epilepsy, excess acid influx, joint pain, and lung swelling. This situation underscores the significance of addressing potential human rights violations in the healthcare sector.